Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02279719 · ClinicalTrials.gov registry record · Phase 1
A Study of BBI608 in Combination With Sorafenib, or BBI503 in Combination With Sorafenib in Adult Patients With Hepatocellular Carcinoma
A Phase 1 study, sponsored by Sumitomo Pharma America.
- Completed
- Registry status
- Phase 1
- Development phase
- 97
- Enrollment target
NCT02279719 is a Phase 1 study that has completed, run by Sumitomo Pharma America. The registered enrollment target is 97 participants.
The verdict
NCT02279719, a Phase 1 study, has completed, sponsored by Sumitomo Pharma America.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 97 participants
- Enrollment target
Study Summary
This is an open label, three-arm, phase 1 dose escalation study and phase 2 study of BBI608 in combination with sorafenib, or BBI503 in combination with sorafenib. The study population is adult patients with advanced hepatocellular carcinoma who have not received systemic chemotherapy.
Interventions
- DRUG Sorafenib
- DRUG BBI608
- DRUG BBI503
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 97 participants |
| Start Date | 2014-12 |
| Est. Completion | 2019-10 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02279719
The ClinicalTrials.gov registry entry for NCT02279719 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 97 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sumitomo Pharma America, which has 168 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Sorafenib is the first listed.
NCT02279719 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02279719 about?
NCT02279719 is a clinical study titled "A Study of BBI608 in Combination With Sorafenib, or BBI503 in Combination With Sorafenib in Adult Patients With Hepatocellular Carcinoma". This is an open label, three-arm, phase 1 dose escalation study and phase 2 study of BBI608 in combination with sorafenib, or BBI503 in combination with sorafenib. The study population is adult patients with advanced hepatocellular carcinoma who have not received systemic chemotherapy.
What is the current status of trial NCT02279719?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 97 participants. The study started on 2014-12. Estimated completion is 2019-10.
What interventions are being tested in trial NCT02279719?
The interventions under investigation include: Sorafenib (DRUG), BBI608 (DRUG), BBI503 (DRUG).
Who is sponsoring clinical trial NCT02279719?
This trial is sponsored by Sumitomo Pharma America, which has 168 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.